Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT200 in Type 2B Von Willebrand Disease
NCT07273721Phase 2Recruiting
- Sponsor
- Medical University of Vienna
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
Phase 2, randomised trial of rondaptivon pegol in von Willebrand disease type 2B (VWD2B) (2 arms), sponsored by Medical University of Vienna. Primary endpoints: Platelet Counts at 5 weeks and Clinically evident bleeding at 5 weeks. Started Aug 2025; status: recruiting.
02
Drugs
rondaptivon pegol
03
Conditions
von Willebrand disease type 2B (VWD2B)
Beyond the preview
Go deeper on NCT07273721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07273721.